T 1437/21 (Empagliflozin/BOEHRINGER INGELHEIM) of 09.02.2024

European Case Law Identifier: ECLI:EP:BA:2024:T143721.20240209
Date of decision: 9 February 2024
Case number: T 1437/21
Petition for review of: -
Application number: 14715578.2
IPC class: A61P 3/10 A61P 13/12 A61K 31/7048
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: THERAPEUTIC USES OF EMPAGLIFLOZIN
Applicant name: Boehringer Ingelheim International GmbH
Opponent name: KRKA, d.d., Novo mesto
EGIS Gyógyszergyár Zártkörüen Müködö
Részvénytársaság
Teva Pharmaceutical Industries Ltd.
Stada-Arzneimittel Aktiengesellschaft
Generics (U.K.) Limited
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Gillard, Richard Edward
Board: 3.3.07
Headnote: -
Relevant legal provisions: European Patent Convention Art 54 European Patent Convention Art 56 European Patent Convention Art 83
Keywords: Amendments - allowable (yes)
Sufficiency of disclosure - (yes)
Novelty (yes)
Novelty - second (or further) medical use
Inventive step (yes)
Inventive step - no reasonable expectation of success
Catchword: -
Cited cases: T 2506/12 T 0239/16 T 1123/16 T 2963/19
Citing cases: T 0122/23 T 1934/23 T 0136/24 T 0792/24

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is maintained as granted.